AVITA Medical (RCEL) CFO adds 2,000 shares in open-market buy

Rhea-AI Filing Summary

AVITA Medical, Inc. CFO David D. O'Toole reported an open-market purchase of 2,000 shares of common stock at a price of $4.26 per share. Following this transaction, he directly holds 145,927 shares, which the disclosure states include unvested restricted stock units.

Insider Trade Summary

Net Buyer: 2,000 shares ($8,520)

Net Buy 1 txn

Insider O'Toole David D

Role CFO

Bought 2,000 shs ($9K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,000	$4.26	$9K

Holdings After Transaction: Common Stock — 145,927 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 2,000 shares Purchase price: $4.26 per share Shares held after transaction: 145,927 shares

3 metrics

Shares purchased 2,000 shares Open-market purchase of common stock

Purchase price $4.26 per share Price paid for the 2,000 purchased shares

Shares held after transaction 145,927 shares Direct holdings after the reported purchase

Key Terms

open-market purchase, restricted stock units, Form 4

3 terms

open-market purchase financial

"reported an open-market purchase of 2,000 shares of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

restricted stock units financial

"the disclosure states include unvested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Form 4 regulatory

"This Form 4 filing reflects a direct acquisition of additional equity"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Toole David D

(Last) (First) (Middle)

28159 AVENUE STANFORD

SUITE 220 - AVITA MEDICAL

(Street)

VALENCIA CALIFORNIA 91355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AVITA Medical, Inc. [ RCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/20/2026		P		2,000	A	$4.26	145,927(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes unvested RSUs

	/s/ David O'Toole	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did AVITA Medical (RCEL) report for its CFO?

AVITA Medical reported that CFO David D. O'Toole made an open-market purchase of 2,000 shares of common stock at $4.26 per share. This Form 4 filing reflects a direct acquisition of additional equity in the company.

At what price did the AVITA Medical (RCEL) CFO buy shares?

The CFO bought 2,000 AVITA Medical common shares at $4.26 per share in an open-market transaction. This fixed purchase price is disclosed in the Form 4 and applies to the entire reported transaction.

How many AVITA Medical (RCEL) shares does the CFO hold after this transaction?

After the reported purchase, CFO David D. O'Toole directly holds 145,927 shares of AVITA Medical common stock. The filing notes that this total includes unvested restricted stock units, reflecting both vested and certain unvested equity awards.

Is the AVITA Medical (RCEL) CFO’s Form 4 transaction a buy or sell?

The Form 4 transaction is a buy. It is classified as an open-market purchase of 2,000 AVITA Medical common shares, with no shares reported as sold in this particular insider filing.

Does the AVITA Medical (RCEL) Form 4 mention restricted stock units (RSUs)?

Yes. A footnote in the Form 4 states that the CFO’s reported total holdings of 145,927 shares include unvested restricted stock units, indicating some of his equity position is still subject to vesting conditions.